Blog
CLASSIC LIST
January 17, 2024 Uncategorized
Our experience with Gott Marketing has been nothing short of exceptional. As a specialized marketing agency catering to the building products and construction industry, we initially approached Gott Marketing with specific industry-related concerns. However, our collaboration took an unexpected turn when we needed a new website for Arlington Skin Doctor.
Despite their primary focus on the construction sector, the team at Gott Marketing went above and beyond to accommodate our needs. They not only accepted the challenge of revamping our website but also demonstrated their versatility in tailoring their services to different industries.
From the initial consultation to the final rollout, the Gott Marketing team exhibited professionalism, creativity, and an in-depth understanding of our unique requirements. The result was a website that not only met but exceeded our expectations. The user-friendly design, seamless navigation, and visually appealing layout have significantly enhanced our online presence.
Gott Marketing’s commitment to delivering high-quality solutions and their willingness to adapt to diverse industries showcase their dedication to client satisfaction. We appreciate their flexibility, expertise, and the collaborative spirit that made our website redesign project a success.
For any business, regardless of industry, looking for a marketing agency that combines specialization with adaptability, Gott Marketing is undoubtedly a top choice. Their ability to pivot and deliver outstanding results sets them apart in the competitive landscape of marketing agencies.
Thank you, Gott Marketing, for your outstanding work and commitment to ensuring our online presence aligns with our brand values.
April 12, 2023 Clinical Trials Coming Soon
If you have hair loss you may be suffering from a condition called Alopecia. A new Topical cream study for ages 18 and older.
If interested, contact us at 817-755-5542 or email us at studies@acderm.com
April 12, 2023 Clinical Trials
Atopic Dermatitis Sleep Disturbances
New topica creaml study for 18 years and older.
Arlington Research Center is looking for adults, aged 18 years and up who have eczema and resulting sleep disturbances, to participate in a clinical research study evaluating an investigational cream.
How can you participate?
Inquire about how you can participate in this study today.
TO LEARN MORE ABOUT THE INTEGUMENT STUDY, CONTACT:
studies@acderm.com or call 817-795-7546 ext. 339 or Text 817-755-5542.
April 12, 2023 Newsletter
Atopic Dermatitis (AD) is a common, chronic, inflammatory skin condition characterized by persistent itchiness, dryness and lesions or cracking or flaking skin. It is commonly called Eczema and can include skin eruptions, redness, bumps, and lesions that may spread, depending on the patient’s age and varying extents of skin dryness. It is estimated that one in ten Americans suffer with Atopic Dermatitis.
Recently a group of dermatology researchers set out to provide a summary of plausible explanations for why AD may be related, with greater prevalence, to certain cardiovascular diseases, neuropsychiatric diseases (such as epilepsy, autism, attention deficit hyperreactivity disorder, and depression), autoimmune diseases (alopecia areata, vitiligo, rheumatoid diseases, type I diabetes (T1D)), and obesity.
To prove their hypothesis, the authors looked for supporting literature using the PubMed database with search queries “atopic dermatitis and comorbidities”, “atopic dermatitis and cardiovascular comorbidities,” “atopic dermatitis and neurological comorbidities,” “atopic dermatitis and psychiatric comorbidities” and “atopic dermatitis and autoimmune comorbidities.”
Based on the analysis of titles and abstracts, the researchers included articles on the causes of the increased co-occurrence of atopic dermatitis, including genetic factors, immunological factors, and exposure to modifiable risk factors.
Medical research has previously established that regular physical activity aids in the primary and secondary prevention of a number of chronic diseases including obesity, depression, and cardiovascular diseases. Researchers in this study found research that linked adult AD with decreased physical activity in the USA. Patients with eczematous skin lesions on their palms and soles might find it difficult to participate in a variety of activities, but also elevated skin temperature and perspiration are known flare triggers for AD outbreaks. Additionally, sleep disturbance and depression, which often occur in AD patients, can make it more difficult to maintain a regular exercise routine.
AD was also found to be associated with an increased incidence of eating disorders, with bulimia nervosa and binge eating disorder being the most prevalent, with the researchers explaining that incorrect administration of a systemic treatment for AD can be a factor in these issues.
Regarding cardiovascular disease, the authors found contrasting opinions in studies that looked at a possible link with AD. In one study, a 1-year history of AD in the United States was associated with a higher prevalence of coronary artery disease, angina pectoris, myocardial infarction, stroke, and peripheral vascular disease. But in a German study, AD patients experienced an elevated risk of angina pectoris, hypertension, and PVD, but not of MI or stroke. The authors explained this by noting that a variation in endotypes and lifestyle choices between the countries could account for the observed differences.
While the higher cardiovascular risk in psoriatic patients as, at least to some extent, a result of elevated levels of immune and cardiovascular proteins is a well-established concern, the data on AD are less researched and still emerging.
Some of the other research findings theorized that AD increases blood platelet activation and oxidative stress while decreasing fibrinolysis—both of which could be contributing factors to the development of thrombosis. Yet different studies indicated that the function of platelet aggregation was not impaired in AD patients, claiming that a higher activity of proinflammatory mast cells and tryptases decreased the risk of thrombosis by tryptase-mediated degradation of fibrinogen, a thrombosis mediator, and creation of a complex between heparin and tryptase, resulting in anticoagulation.
Based on their overall findings, the researchers concluded that AD is indeed associated with multiple comorbid allergic, cardiovascular, mental health, neurologic, autoimmune, and metabolic conditions.
Still, they warn that it’s vital to determine the extent to which this coexistence is linked to exposure to, often modifiable, risk factors, as well as genetics and immune dysregulations.
Another key point they shared is analyzing the immunology of chronic inflammation whose correction, activation, or suppression would theoretically aid in preventing the development of a variety of comorbidities.
More research is needed to determine how non-dermatology conditions contribute to dermatological diseases. Clinicians and patients should be made aware of non-allergic comorbidities associated with AD and attempt to detect them and treat them as a potential contributors to AD conditions. Treatment of non-dermatological condition may affect changes in conditions like AD.
Do you have AD? Do you have other conditions described in this article that might be contributing to your dry, itchy skin? Dr. Moore and her team offer a variety of treatments for AD. Dr. Moore also participates in a number of Atopic Dermatitis clinical trials that will offer free medicine and free treatment for AD. Text or call us at 817-755-5542 to see if you qualify for an AD clinical trial. Learn more at www.arlingtonskindoctor.com.
Source: Dermatology Times March 2023
April 12, 2023 Newsletter
Exposure to the sun may actually increase acne breakouts. Proper sun-protection in patients with acne or acne-prone skin can lead to skin improvements and better patient outcomes.
In a recent study, researchers sought to determine the impact of sun exposure on acne. Additionally, the study set out to explore the use of photoprotection as it relates to improving outcomes in the treatment of acne.
In order to determine a potential correlation, researchers conducted an extensive narrative review of previous studies, journal articles, and relevant literature. They collected data from Google Scholar and PubMed searchers from January 1992 to November 2022. Of these, researchers accumulated several articles, clinical trials, meta-analyses, observational studies, and review articles. Within the search, researchers used keywords, including acne, cosmeceuticals, cosmetics, dermocosmetics, diet, etiology, exposome, lack of sleep, pathogenesis, photoprotection, pigmentary disorders, pollution, post-inflammatory hyperpigmentation, stress, sunlight, sunscreens, ultraviolet radiation, and visible light. After accumulating prior research, researchers also established a list of physiopathological factors in acne. These included genetic predisposition, hyperkeratinization, sebum production and composition, hormones, inflammation and inflammasomes, and other life long sun-exposure factors.
Environmental factors or extensive, life-long exposures to the sun’s radiation, rather than genetic factors, may be more important to health and may generate most health disparities, researchers concluded.
Examples of life-long issues in patients with acne, according to the study, include sun exposure, environmental humidity, pollution of large cities, a non-balanced diet, microorganisms, stress, lack of sleep, mental health, low-quality cosmetics or non-appropriately chosen cosmetics, oral supplements, and medications. Researchers concluded that sunlight and UV light are mistakenly thought to be beneficial for acne and can be used as a treatment. The relationship between acne and photoexposure is complicated researchers observed. They concluded that some patients showed a reduction in acne related inflammatory lesions in summer, yet others experienced flares or worsening. According to researchers, one study included in the analysis revealed that more than 50% of individuals with acne experienced flares or worsening in the summer months. In another study, nearly 50% presented with seasonal variation in their acne, with 40% reporting worsening in the summer months. Researchers also found that particularly in patients with skin of color, sun exposure in acne could lead to post-inflammatory hyperpigmentation or erythema. Additionally, some common acne treatments possess photosensitizing effects, such as isotretinoin or tetracyclines, such as doxycycline. In patients taking these medications, sun exposure and high levels of solar radiation can lead to phototoxic reactions. Of the several conditions of environmental exposure included in the study, researchers found that factors such as pollution, nutrition, harsh skincare, stress, and sun exposure were the most impactful in patients with acne.
Sun radiation may not improve acne and can actually aggravate acne and induce long-lasting after-effects connected with acne. Daily photoprotection is highly recommended to all individuals with acne. Broad-spectrum sunscreens with physical blockers like zinc, not only protect from solar radiation and its negative consequences, but can also provide significant skin hydration, enhance the skin barrier function and reduce trans-epidermal water loss (TEWL). Sunscreens can also protect from pollution and can provide sebum-regulating, depigmenting, anti-inflammatory and antioxidant active properties.
Acne treatment can be challenging and often requires more attention and treatment beyond over the counter solutions. Dr. Moore and her team of dermatology providers can offer you significant options for treatment of acne, even persistent and difficult to treat acne. Dr. Moore also participates in Clinical Trials that offer free medication and free treatment of acne. Check with your dermatology provider in our office to see if you qualify for a clinical trial treatment of acne today. Contact us at 817-795-7546 x339 or go to https://www.arlingtonskindoctor.com/clinical-trials/ to learn more.
Source: DERMATOLOGY TIMES MARCH 2023
April 12, 2023 Newsletter
The FDA has recently approved Baricitinib (Olumiant; Eli Lilly and Company), an oral Janus kinase (JAK) inhibitor, to treat patients with alopecia areata (significant hair loss) (AA). AA is an autoimmune disorder that makes hair fall out as the body attacks the hair follicles. This disorder affects more than 300,000 people in the U.S. each year. This is the first FDA approval of a systemic treatment for AA.
Clinical trials have shown baricitinib to be safe and effective in the treatment of severe alopecia. It is anticipated that baricitinib will help fulfill a significant unmet need for patients with severe alopecia areata. The data behind the approval comes from 2 trials which were randomized, double-blind, placebo-controlled trials containing patients who had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool for more than 6 months. Those in the trial were placed into 1 of 3 arms—placebo, 2 mgs of baricitinib, or 4 mgs baricitinib—every day. The key primary endpoint of the trials was the proportion of patients who achieved at least 80% scalp hair coverage at week 36.
In the first trial it was found that 22% of the 184 patients who received 2 milligrams of baricitinib achieved adequate scalp hair coverage compared to 35% of the 281 patients who received 4 milligrams of baricitinib. Five percent of the 189 patients who received a placebo.
In the second trial it was found that 17% of the 156 patients who received 2 milligrams of baricitinib achieved adequate scalp hair coverage compared to 32% of the 234 patients who received 4 milligrams of baricitinib. Three percent of the 156 patients who received a placebo.
Common adverse events in the use of baricitinib included upper respiratory tract infections, headache, acne, high cholesterol (hyperlipidemia), increase of an enzyme called creatinine phosphokinase, urinary tract infection,liver enzyme elevations, inflammation of hair follicles (folliculitis), fatigue, lower respiratory tract infections, nausea, genital yeast infections (Candida infections), anemia, low number of certain types of white blood cells (neutropenia), abdominal pain, shingles (herpes zoster) and weight increase.
Baricitinib (Olumiant) was originally approved in 2018. It is approved as a treatment for certain adult patients with moderately to severely active rheumatoid arthritis. Olumiant is also approved for the treatment of COVID-19 in certain hospitalized adults.
Dr. Moore and her dermatology team provide a number for solutions for hair loss. Dr. Moore also participates in ongoing research on hair loss treatment for alopecia areata. Call or text us at 817-755-5542 for more information or go to https://www.arlingtonskindoctor.com/clinical-trials/ to see if you qualify for free medication and free treatment for alopecia areata.
Source: FDA website, 2022; DERMATOLOGY TIMES, June 2022
April 12, 2023 Clinical Trials Coming Soon
Hidradenitis Suppurativa – upcoming study
We know life with Hidradenitis Suppurativa isn’t always easy.
There are many unanswered questions surrounding the causes of HS and the painful and distressing symptoms it triggers in the body. With limited approved medical treatment options available, it’s important to keep looking for potential answers.
Call 817-795-7546 or email studies@acderm.com if you think you would like to participate in this study.
April 12, 2023 Clinical Trials
Arlington Research Center is looking for children and adults, aged 6 years and up who have eczema, to participate in a clinical research study evaluating an investigational cream. This study includes up to 5 visits for 2 months.
Studies for youth and adults. Must have a history of atopic dermatitis for at least 3 months for youth 6-17 years of age, and for at least 6 months for adults 18 years and older. Study patients previously on the ARQ-151 are excluded.
Also have a Atopic dermatitis study with an injection medication for patients 12 years of age and older
How can you participate?
Inquire about how you can participate in this study today.
TO LEARN MORE ABOUT THE INTEGUMENT STUDY, CONTACT:
studies@acderm.com or call 817-795-7546 ext. 339 or Text 817-755-5542.
April 12, 2023 Clinical Trials
New topical study for ages 2-12 years old. This study focuses on the scalp and body.
While severe psoriasis affects the skin, causing it to itch and burn, it can also have an emotional impact on adolescents, as well as their parents.
Because of the raised, red, scaly patches on their skin, many adolescents feel ashamed or embarrassed by their condition. These emotions can cause them to not want to hang out with friends, attend school functions, or participate in extracurricular activities.
For parents watching these physical and emotional effects, it’s difficult when other treatments have not been successful in managing their child’s psoriasis.
Because many adolescents and their families struggle with psoriasis, this research study is being conducted to evaluate an investigational drug for severe psoriasis. In this study, researchers want to learn more about the safety and effectiveness of the investigational drug.
The investigational drug has not been approved by any regulatory agency for the treatment of children and adolescents with this condition. It is only available to children and adolescents in research studies like this one.
The results of this study will provide more information about the investigational drug and whether it could one day be approved for children and adolescents with severe plaque psoriasis.
Who is eligible to participate in this study?
To be eligible for this study, patients must:
- Be 6 to 12 years of age
- Have been diagnosed with chronic plaque psoriasis
All study-related visits, tests, and drugs will be provided at no cost. In addition, compensation for study-related travel may be provided.
Associations
